Professor Philip Barter

Al Sayed N; Al Waili K; Alawadi F; Al-Ghamdi S; Al Mahmeed W; Al-Nouri F; Al Rukhaimi M; Al-Rasadi K; Awan Z; Farghaly M, 2016, 'Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East', International Journal of Cardiology, vol. 225, pp. 268 - 283, http://dx.doi.org/10.1016/j.ijcard.2016.09.081

Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L, 2016, 'In vivo PET imaging with [¹⁸F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes', Diabetologia, vol. 59, pp. 1977 - 1984, http://dx.doi.org/10.1007/s00125-016-3993-5

Geronimo FRB; Barter PJ; Rye KA; Heather AK; Shearston KD; Rodgers KJ, 2016, 'Plaque stabilizing effects of apolipoprotein A-IV', Atherosclerosis, vol. 251, pp. 39 - 46, http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.019

Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC, 2016, 'Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia P', The Lancet Diabetes and Endocrinology, vol. 4, pp. 850 - 861, http://dx.doi.org/10.1016/S2213-8587(16)30041-9

Sultana A; Cochran BJ; Tabet F; Patel M; Torres LC; Barter PJ; Rye KA, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', FASEB Journal, vol. 30, pp. 2324 - 2335, http://dx.doi.org/10.1096/fj.201500026R

Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; Van Hall G, 2016, 'Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial', Metabolism: Clinical and Experimental, vol. 65, pp. 904 - 914, http://dx.doi.org/10.1016/j.metabol.2016.03.002

Tabet F; Torres LFC; Ong KL; Shrestha S; Choteau SA; Barter PJ; Clifton P; Rye KA, 2016, 'High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0151061

Barter PJ; Rye KA, 2016, 'Coronary artery disease: Scavenger receptor class B1-a target to reduce CHD risk?', Nature Reviews Cardiology, vol. 13, pp. 249 - 250, http://dx.doi.org/10.1038/nrcardio.2016.50

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2016, 'A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients with Hypertriglyceridemia', American Journal of Cardiology, vol. 117, pp. 1444 - 1448, http://dx.doi.org/10.1016/j.amjcard.2016.02.011

Barter PJ; Rye KA, 2016, 'New era of lipid-lowering drugs', Pharmacological Reviews, vol. 68, pp. 458 - 475, http://dx.doi.org/10.1124/pr.115.012203

Barter PJ; Rye KA, 2016, 'Cholesteryl ester transfer protein inhibition is not yet dead - Pro', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, pp. 439 - 441, http://dx.doi.org/10.1161/ATVBAHA.115.306879

Puranik R; Bao S; Bonin AM; Kaur R; Weder JE; Casbolt L; Hambley TW; Lay PA; Barter PJ; Rye KA, 2016, 'A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo', Cell and Bioscience, vol. 6, http://dx.doi.org/10.1186/s13578-016-0076-8

Rye KA; Barter PJ; Cochran BJ, 2016, 'Apolipoprotein A-I interactions with insulin secretion and production', Current Opinion in Lipidology, vol. 27, pp. 8 - 13, http://dx.doi.org/10.1097/MOL.0000000000000253

Nicholls SJ; Puri R; Wolski K; Ballantyne CM; Barter PJ; Brewer HB; Kastelein JJP; Hu B; Uno K; Kataoka Y, 2016, 'Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial', American Journal of Cardiovascular Drugs, vol. 16, pp. 55 - 65, http://dx.doi.org/10.1007/s40256-015-0146-z

Barter PJ; Tabet F; Rye KA, 2015, 'Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?', Journal of lipid research, vol. 56, pp. 2045 - 2047, http://dx.doi.org/10.1194/jlr.C063768

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis', European Journal of Preventive Cardiology, vol. 23, pp. 744 - 747, http://dx.doi.org/10.1177/2047487315598710

Barter PJ; Rye KA, 2015, 'Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?', Clinical Therapeutics, vol. 37, pp. 2716 - 2731, http://dx.doi.org/10.1016/j.clinthera.2015.07.021

Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D, 2015, 'Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial', American Heart Journal, vol. 170, pp. 1061 - 1069, http://dx.doi.org/10.1016/j.ahj.2015.09.007

Rye KA; Barter PJ; Brown AJ, 2015, 'Speed kills in more ways than one: Methamphetamine and atherosclerosis', Atherosclerosis, vol. 243, pp. 654 - 655, http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.034

Bisoendial R; Tabet F; Tak PP; Petrides F; Cuesta Torres LF; Hou L; Cook A; Barter P; Weninger W; Rye KA, 2015, 'Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis', Arteriosclerosis, Thrombosis, and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.115.305777

Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA, 2015, 'Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis', International Journal of Cardiology, vol. 199, pp. 204 - 212, http://dx.doi.org/10.1016/j.ijcard.2015.07.014

Barter PJ; Nicholls SJ; Kastelein JJP; Rye KA, 2015, 'Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk?: CETP inhibition as a strategy to reduce cardiovascular risk: The pro case', Circulation, vol. 132, pp. 423 - 432, http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014025

Ong KL; Januszewski AS; O Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR, 2015, 'Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, vol. 58, pp. 2035 - 2044, http://dx.doi.org/10.1007/s00125-015-3652-2

Hovingh GK; Kastelein JJP; Van Deventer SJH; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ, 2015, 'Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebo-controlled phase 2 trial', The Lancet, vol. 386, pp. 452 - 460, http://dx.doi.org/10.1016/S0140-6736(15)60158-1

Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ, 2015, 'To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Assoc', Atherosclerosis, vol. 241, pp. 450 - 454, http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.029

Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis', Atherosclerosis, vol. 241, pp. 664 - 670, http://dx.doi.org/10.1016/j.atherosclerosis.2015.06.027

Borel AL; Nazare JA; Smith J; Aschner P; Barter P; Van Gaal L; Eng Tan C; Wittchen HU; Matsuzawa Y; Kadowaki T, 2015, 'Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance', International Journal of Obesity, vol. 39, pp. 495 - 501, http://dx.doi.org/10.1038/ijo.2014.163

Ong KL; Ding J; McClelland RL; Cheung BMY; Criqui MH; Barter PJ; Rye KA; Allison MA, 2015, 'Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, vol. 239, pp. 386 - 392, http://dx.doi.org/10.1016/j.atherosclerosis.2015.01.033

Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA, 2015, 'Cholesteryl Ester Transfer Protein Inhibition Enhances Endothelial Repair and Improves Endothelial Function in the Rabbit', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. 628 - 636, http://dx.doi.org/10.1161/ATVBAHA.114.304747

Nazare JA; Smith J; Borel AL; Aschner P; Barter P; Van Gaal L; Tan CE; Wittchen HU; Matsuzawa Y; Kadowaki T, 2015, 'Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA Study)', American Journal of Cardiology, vol. 115, pp. 307 - 315, http://dx.doi.org/10.1016/j.amjcard.2014.10.039

Cochran BJ; Bisoendial RJ; Hou L; Glaros E; Rossy J; Thomas SR; Barter PJ; Rye KA, 2014, 'Apolipoprotein a-I increases insulin secretion and production from pancreatic β-cells via a g-protein-camp-PKA-FOXO1-dependent mechanism', Arteriosclerosis, Thrombosis, and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.114.304131

Karlson BW; Toth PP; Palmer MK; Barter PJ; Nicholls SJ, 2014, 'Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER', IJC Metabolic and Endocrine, vol. 5, pp. 61 - 66, http://dx.doi.org/10.1016/j.ijcme.2014.11.002

Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K, 2014, 'Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: Insights from study of coronary atheroma by intravascular ultrasound: Effect of rosuvastatin', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, pp. 2465 - 2472, http://dx.doi.org/10.1161/ATVBAHA.114.303932

Ong K-L; Januszewski AS; O Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung W-T; Scott RS; Taskinen M-R, 2014, 'The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study', Diabetologia, http://dx.doi.org/10.1007/s00125-014-3458-7

Stegman B; Puri R; Cho L; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS, 2014, 'High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: Insights from SATURN', Diabetes Care, vol. 37, pp. 3114 - 3120, http://dx.doi.org/10.2337/dc14-1121

Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K, 2014, 'Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: Insights from saturn', JACC: Cardiovascular Imaging, vol. 7, pp. 1013 - 1022, http://dx.doi.org/10.1016/j.jcmg.2014.04.019

Ong KL; McClelland RL; Rye KA; Cheung BMY; Post WS; Vaidya D; Criqui MH; Cushman M; Barter PJ; Allison MA, 2014, 'The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: The multi-ethnic study of atherosclerosis', Atherosclerosis, vol. 236, pp. 257 - 262, http://dx.doi.org/10.1016/j.atherosclerosis.2014.07.015

Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR, 2014, 'Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor d', Journal of the American College of Cardiology, vol. 63, pp. 2365 - 2373, http://dx.doi.org/10.1016/j.jacc.2014.02.538

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2014, 'The relationship between total Bilirubin levels and total mortality in older adults: The United States national health and nutrition examination survey (NHANES) 1999-2004', PLoS ONE, vol. 9, http://dx.doi.org/10.1371/journal.pone.0094479

Tabet F; Vickers KC; Cuesta Torres LF; Wiese CB; Shoucri BM; Lambert G; Catherinet C; Prado-Lourenco L; Levin MG; Thacker S, 2014, 'HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells', Nature Communications, vol. 5, http://dx.doi.org/10.1038/ncomms4292

Ong K-L; Rye K-A; Barter PJ; Waters DD; Messig M; DeMicco DA, 2014, 'Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)', American Journal of Cardiology, http://dx.doi.org/10.1016/j.amjcard.2014.02.011

McGrath KC; Li XH; Whitworth PT; Kasz R; Tan JT; McLennan SV; Celermajer DS; Barter PJ; Rye KA; Heather AK, 2014, 'High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation', Journal of Lipid Research, vol. 55, pp. 421 - 430, http://dx.doi.org/10.1194/jlr.M043281

Rye KA; Barter PJ, 2014, 'Thematic review series: High density lipoprotein structure, function, and metabolism cardioprotective functions of HDLs 1', Journal of Lipid Research, vol. 55, pp. 168 - 179, http://dx.doi.org/10.1194/jlr.R039297

Fruchart JC; Davignon J; Hermans MP; Al-Rubeaan K; Amarenco P; Assmann G; Barter P; Betteridge J; Bruckert E; Cuevas A, 2014, 'Residual macrovascular risk in 2013: What have we learned?', Cardiovascular Diabetology, vol. 13, http://dx.doi.org/10.1186/1475-2840-13-26

Ong KL; Barter PJ; Waters DD, 2014, 'Cardiovascular drugs that increase the risk of new-onset diabetes', American Heart Journal, http://dx.doi.org/10.1016/j.ahj.2013.12.025

Rye KA; Barter PJ, 2014, 'Regulation of high-density lipoprotein metabolism', Circulation Research, vol. 114, pp. 143 - 156, http://dx.doi.org/10.1161/CIRCRESAHA.114.300632

Wu BJ; Ong KL; Shrestha S; Chen K; Tabet F; Barter PJ; Rye K-A, 2013, 'Inhibition of arthritis in the Lewis Rat by apolipoprotein A-I and reconstituted high-density lipoproteins', Arteriosclerosis, Thrombosis, and Vascular Biology, http://dx.doi.org/10.1161/ATVBAHA.113.302832

Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K, 2013, 'C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy', Circulation, vol. 128, pp. 2395 - 2403, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004243

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2013, 'Arthritis: Its prevalence, Risk factors, And association with cardiovascular diseases in the United States, 1999 to 2008', Annals of Epidemiology, vol. 23, pp. 80 - 86, http://dx.doi.org/10.1016/j.annepidem.2012.11.008

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye KA, 2013, 'Trends in C-reactive protein levels in US adults from 1999 to 2010', American Journal of Epidemiology, vol. 177, pp. 1430 - 1442, http://dx.doi.org/10.1093/aje/kws443

Chapman MJ; Giral P; Barter PJ, 2013, 'The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: Insight from EPIC-Norfolk and JUPITER', European Heart Journal, vol. 34, pp. 1318 - 1320, http://dx.doi.org/10.1093/eurheartj/eht074

Wu BJ; Chen K; Shrestha S; Ong KL; Barter PJ; Rye KA, 2013, 'High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3β-hydroxysteroid-[INCREMENT]24 reductase expression and inducing heme oxygenase-1', Circulation Research, vol. 112, pp. 278 - 288, http://dx.doi.org/10.1161/CIRCRESAHA.111.300104

Wu BJ; Shrestha S; Ong KL; Johns DG; Barter PJ; Rye K-A, 2012, 'Effects of Cholesteryl Ester Transfer Protein Inhibition on Endothelial Repair and Function', CIRCULATION, vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Ong KL; Allison MA; Cheung BMY; Wu BJ; Barter PJ; Rye K-A, 2012, 'C-Reactive Protein Trends and Associations with Total Mortality in United States Adults between 1999-2010', CIRCULATION, vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885000078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Ong KL; Rye K-A; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-binding Protein 4 in Subjects With Type 2 Diabetes', CIRCULATION, vol. 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885001409&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC, 2012, 'Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 97, pp. 4701 - 4708, http://dx.doi.org/10.1210/jc.2012-2267

Ong KL; Barter PJ; Rye KA, 2011, 'Response to statin use and serum bilirubin levels', Atherosclerosis, vol. 219, pp. 392, http://dx.doi.org/10.1016/j.atherosclerosis.2011.09.007

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye KA, 2011, 'Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008', Atherosclerosis, vol. 219, pp. 728 - 733, http://dx.doi.org/10.1016/j.atherosclerosis.2011.07.094

Ong KL; Wu BJ; Cheung BMY; Barter PJ; Rye K-A, 2011, 'Arthritis: Its Prevalence, Risk Factors, and Association with Cardiovascular Diseases in the United States National Health and Nutrition Examination Survey 1999-2008', CIRCULATION, vol. 124, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299738703116&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Fryirs MA; Barter PJ; Appavoo M; Tuch BE; Tabet F; Heather AK; Rye KA, 2010, 'Effects of high-density lipoproteins on pancreatic β-cell insulin secretion', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, pp. 1642 - 1648, http://dx.doi.org/10.1161/ATVBAHA.110.207373

Patel S; Di Bartolo BA; Nakhla S; Heather AK; Mitchell TW; Jessup W; Celermajer DS; Barter PJ; Rye KA, 2010, 'Anti-inflammatory effects of apolipoprotein A-I in the rabbit', Atherosclerosis, vol. 212, pp. 392 - 397, http://dx.doi.org/10.1016/j.atherosclerosis.2010.05.035

Patel S; Puranik R; Nakhla S; Lundman P; Stocker R; Wang XS; Lambert G; Rye KA; Barter PJ; Nicholls SJ, 2009, 'Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins', Atherosclerosis, vol. 204, pp. 424 - 428, http://dx.doi.org/10.1016/j.atherosclerosis.2008.07.047

Wadham C; Albanese N; Roberts J; Wang L; Bagley CJ; Gamble JR; Rye KA; Barter PJ; Vadas MA; Xia P, 2004, 'High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity', Circulation, vol. 109, pp. 2116 - 2122, http://dx.doi.org/10.1161/01.CIR.0000127419.45975.26

Rye KA; Duong M; Psaltis MK; Curtiss LK; Bonnet DJ; Stocker R; Barter PJ, 2002, 'Evidence that phospholipids play a key role in pre-β apoA-I formation and high-density lipoprotein remodeling', Biochemistry, vol. 41, pp. 12538 - 12545, http://dx.doi.org/10.1021/bi025998k